Julian Rees, HOPO Therapeutics CEO (Credit: Majed Abolfazli)

HOPO Ther­a­peu­tics wins up to $226M BAR­DA con­tract for heavy met­al poi­son­ing re­search

HOPO Ther­a­peu­tics scored a gov­ern­ment con­tract for up to $226 mil­lion to de­vel­op an oral coun­ter­mea­sure against ra­di­o­log­i­cal threats and heavy met­al poi­son­ing.

The fund­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.